Drug Metabolism and Liver Enzymes: How Your Body Processes Medicine

Why Drug Metabolism Exists

The body cannot excrete highly lipophilic (fat-soluble) molecules efficiently through the kidneys because these molecules are passively reabsorbed from the renal tubule back into the blood. Without metabolic transformation, many drugs would remain in the body for weeks or months, accumulating to toxic levels with repeated dosing. Drug metabolism solves this problem by converting lipophilic molecules into hydrophilic (water-soluble) metabolites that the kidneys can excrete.

This system did not evolve to handle pharmaceutical drugs. It evolved over hundreds of millions of years to process the countless foreign organic molecules, called xenobiotics, that organisms encounter through diet and environmental exposure. Plant alkaloids, dietary flavonoids, environmental pollutants, bacterial toxins, and the products of food degradation are all substrates for the same metabolic machinery that processes modern drugs. The system is remarkably versatile, capable of handling an enormous diversity of chemical structures, precisely because it evolved to deal with an unpredictable and constantly changing array of environmental chemicals.

Phase I Metabolism: Functionalization

Phase I reactions introduce or unmask a functional group (such as a hydroxyl, amino, or carboxyl group) on the drug molecule through oxidation, reduction, or hydrolysis. These reactions make the molecule slightly more polar and create a chemical "handle" that Phase II enzymes can attach a conjugating group to.

The cytochrome P450 (CYP) enzymes dominate Phase I metabolism. They are a superfamily of heme-containing monooxygenases embedded in the smooth endoplasmic reticulum of hepatocytes. The name "P450" derives from the observation that these enzymes, when bound to carbon monoxide, absorb light at a wavelength of 450 nanometers. The human genome encodes 57 CYP genes, but just six isoforms handle the metabolism of approximately 90% of clinically used drugs:

CYP3A4 is the most abundant CYP in the liver and intestinal wall, metabolizing roughly 50% of all drugs on the market. Substrates include calcium channel blockers (nifedipine, amlodipine), statins (atorvastatin, simvastatin), HIV protease inhibitors (ritonavir, saquinavir), immunosuppressants (cyclosporine, tacrolimus), benzodiazepines (midazolam, triazolam), macrolide antibiotics (erythromycin), and many cancer drugs. CYP3A4 is also expressed in the intestinal wall, where it contributes to first-pass metabolism of orally administered drugs.

CYP2D6 metabolizes approximately 25% of drugs, including many cardiovascular drugs (metoprolol, propafenone), antidepressants (fluoxetine, paroxetine, venlafaxine), antipsychotics (risperidone, haloperidol), opioids (codeine, tramadol, oxycodone), and the breast cancer drug tamoxifen. CYP2D6 is notable for its extreme genetic variability: over 100 allelic variants have been identified, producing metabolizer phenotypes ranging from poor (5 to 10% of Caucasians have essentially no CYP2D6 activity) to ultrarapid (1 to 2% of Caucasians, up to 29% of some East African populations, have duplicated or amplified CYP2D6 genes with greatly increased activity).

CYP2C9 metabolizes warfarin, phenytoin, losartan, and most NSAIDs. Genetic variants CYP2C9*2 and CYP2C9*3 reduce enzyme activity, causing slower warfarin metabolism and increased bleeding risk at standard doses. The FDA recommends considering CYP2C9 genotype when initiating warfarin therapy.

CYP2C19 metabolizes proton pump inhibitors (omeprazole, lansoprazole), the antiplatelet drug clopidogrel, and several antidepressants. Clopidogrel is a prodrug that requires CYP2C19-mediated activation to produce its active metabolite. Poor metabolizers of CYP2C19 (approximately 2 to 5% of Caucasians, 15 to 20% of East Asians) have reduced clopidogrel activation and increased cardiovascular event risk, leading the FDA to add a black box warning recommending genotype testing before prescribing clopidogrel.

CYP1A2 metabolizes caffeine, theophylline, clozapine, and several other drugs. It is induced by smoking (polycyclic aromatic hydrocarbons in tobacco smoke increase CYP1A2 expression) and by cruciferous vegetables (broccoli, Brussels sprouts). Smokers may require higher doses of CYP1A2-metabolized drugs, and patients who quit smoking may experience toxicity from drugs whose metabolism slows as CYP1A2 induction reverses.

CYP2E1 metabolizes ethanol, acetaminophen, and several volatile anesthetics. It converts a small fraction of acetaminophen to the toxic metabolite NAPQI, a process that becomes clinically significant in overdose situations or in chronic heavy drinkers (who have induced CYP2E1 expression).

Phase II Metabolism: Conjugation

Phase II reactions attach a large, polar molecule to the drug or its Phase I metabolite, dramatically increasing water solubility and facilitating renal or biliary excretion. The resulting conjugates are almost always pharmacologically inactive and are efficiently excreted.

Glucuronidation is the most common Phase II reaction, catalyzed by UDP-glucuronosyltransferase (UGT) enzymes. A glucuronic acid molecule is attached to the drug via an oxygen, nitrogen, or sulfur atom. Substrates include morphine (which is glucuronidated to morphine-3-glucuronide and morphine-6-glucuronide, the latter being pharmacologically active and contributing to analgesia), acetaminophen, ibuprofen, and bilirubin. UGT1A1, which glucuronidates bilirubin, also metabolizes the cancer drug irinotecan; patients with Gilbert syndrome (reduced UGT1A1 activity) are at increased risk of irinotecan toxicity.

Sulfation, catalyzed by sulfotransferases (SULTs), attaches a sulfate group to the drug. It is important for the metabolism of acetaminophen, steroid hormones, and catecholamines. Sulfation has limited capacity because the cofactor PAPS (3'-phosphoadenosine-5'-phosphosulfate) is present in relatively small amounts and can be depleted by high drug loads.

Glutathione conjugation, catalyzed by glutathione S-transferases (GSTs), is particularly important as a detoxification mechanism. Glutathione neutralizes electrophilic reactive metabolites that would otherwise damage cellular proteins and DNA. The critical role of glutathione in acetaminophen safety illustrates this: at therapeutic doses, the small amount of NAPQI generated by CYP2E1 is immediately conjugated with glutathione and safely excreted. In overdose, glutathione stores are depleted, NAPQI accumulates, and hepatocyte death follows.

Acetylation, catalyzed by N-acetyltransferases (NAT1 and NAT2), is important for metabolizing isoniazid (a tuberculosis drug), hydralazine, procainamide, and several sulfonamides. NAT2 exhibits genetic polymorphism, dividing the population into fast and slow acetylators. Slow acetylators (approximately 50% of Caucasians and African Americans, 10 to 15% of East Asians) metabolize isoniazid more slowly and are at increased risk of isoniazid-induced peripheral neuropathy and hepatotoxicity.

Methylation, catalyzed by methyltransferases, processes catecholamines (via COMT, catechol-O-methyltransferase), histamine, and the cancer drug mercaptopurine. Thiopurine S-methyltransferase (TPMT) metabolizes mercaptopurine and azathioprine; patients with low TPMT activity (approximately 10% of the population are intermediate metabolizers, and 0.3% are poor metabolizers) are at high risk of severe bone marrow suppression at standard doses.

Prodrugs: Metabolism as Activation

Not all drug metabolism leads to inactivation. Prodrugs are intentionally designed as inactive (or less active) compounds that require metabolic conversion to release the active drug. Prodrug strategies are used to overcome poor oral absorption, reduce side effects at the site of administration, or improve tissue targeting.

Codeine is a prodrug that requires CYP2D6-mediated O-demethylation to produce morphine, its active metabolite. Poor CYP2D6 metabolizers get little pain relief from codeine because they cannot generate enough morphine. Ultrarapid metabolizers produce morphine so quickly that standard codeine doses can cause opioid toxicity, including respiratory depression. The FDA has contraindicated codeine use in children under 12 and in breastfeeding mothers because of fatal cases in ultrarapid metabolizer children.

Clopidogrel (Plavix) requires two sequential CYP-mediated oxidation steps to form its active thiol metabolite, which irreversibly inhibits the platelet P2Y12 receptor. CYP2C19 is the principal enzyme for the second activation step. Poor CYP2C19 metabolizers have significantly reduced clopidogrel activation and higher rates of cardiovascular events following coronary stent placement.

Enalapril is an ester prodrug that is hydrolyzed in the liver to enalaprilat, the active ACE inhibitor. The ester form was designed because enalaprilat itself has poor oral bioavailability. Levodopa, the primary drug for Parkinson's disease, is a prodrug of dopamine: it crosses the blood-brain barrier (which dopamine itself cannot) and is then converted to dopamine by DOPA decarboxylase in the brain.

Enzyme Induction and Inhibition

Enzyme induction is the process by which exposure to certain substances increases the transcription and synthesis of metabolic enzymes, particularly CYPs. Induction develops gradually over 1 to 3 weeks as new enzyme protein accumulates and reverses over a similar period after the inducer is removed. The nuclear receptors PXR (pregnane X receptor) and CAR (constitutive androstane receptor) mediate most CYP induction by binding inducer molecules and activating gene transcription.

Clinically important inducers include rifampin (the most potent, inducing CYP3A4, CYP2C9, CYP2C19, and UGTs), carbamazepine, phenytoin, phenobarbital, chronic alcohol consumption, smoking, and St. John's wort. The clinical consequence is reduced plasma concentrations and reduced effectiveness of co-administered drugs. Rifampin has caused oral contraceptive failure, organ transplant rejection (by reducing cyclosporine levels), and antiretroviral therapy failure.

Enzyme inhibition occurs when a substance binds to a CYP enzyme and reduces its catalytic activity. Inhibition can be reversible (competitive, where the inhibitor competes with the substrate for the active site, or noncompetitive) or irreversible (mechanism-based, where the inhibitor forms a covalent bond with the enzyme, permanently inactivating it). Reversible inhibition takes effect quickly and reverses when the inhibitor is cleared. Irreversible inhibition persists until new enzyme is synthesized.

Important CYP3A4 inhibitors include ketoconazole, itraconazole, ritonavir, clarithromycin, erythromycin, grapefruit juice, and diltiazem. Ritonavir's potent CYP3A4 inhibition is actually exploited therapeutically in HIV treatment: it is given in low doses alongside other protease inhibitors specifically to boost their plasma levels (pharmacokinetic boosting). Important CYP2D6 inhibitors include fluoxetine, paroxetine, and quinidine. Important CYP1A2 inhibitors include fluvoxamine and ciprofloxacin.

Extrahepatic Metabolism

Although the liver is the dominant metabolic organ, drug metabolism also occurs in other tissues. The intestinal wall expresses CYP3A4 and UGTs, contributing significantly to first-pass metabolism of orally administered drugs. The kidneys perform glucuronidation and some CYP-mediated reactions. The lungs metabolize some inhaled drugs and endogenous substrates. The blood contains esterases that hydrolyze ester-containing drugs (succinylcholine is rapidly hydrolyzed by plasma cholinesterase, which is why its neuromuscular blocking effect lasts only minutes). The gut microbiome performs a variety of metabolic reactions, including the hydrolysis of glucuronide conjugates excreted in bile (facilitating enterohepatic recirculation) and the reduction of certain drug molecules.

The role of the gut microbiome in drug metabolism is an active area of research. Bacterial enzymes can activate prodrugs (sulfasalazine is cleaved by colonic bacteria to release the active anti-inflammatory component 5-aminosalicylic acid), inactivate drugs, produce toxic metabolites, or alter bile acid metabolism in ways that affect drug absorption. Individual variation in gut microbiome composition may contribute to variability in drug response, adding another layer of complexity to personalized medicine.